New and emerging pharmacologic treatments for MDD.

Major depressive disorder (MDD) remains a major global health problem, and traditional antidepressants often work slowly or not at all—up to 60% of patients do not respond adequately. This review describes emerging pharmacologic treatments that target neurobiological pathways beyond the usual monoamine systems. Ketamine and S-ketamine produce rapid antidepressant effects, often within hours, by blocking NMDA receptors and enhancing synaptic plasticity; these effects can last several days after a single dose, especially in treatment-resistant cases. A combination of dextromethorphan and bupropion also shows quicker and more durable benefits than either drug alone. Neurosteroids like brexanolone (given intravenously) and zuranolone (oral) effectively treat postpartum depression by modulating GABA-A receptors. New agents acting on opioid pathways, such as esmethadone and selective kappa receptor antagonists, offer additional novel approaches.

Study at a glance

Abstract

Major depressive disorder (MDD) presents a significant global health challenge, characterized by a high prevalence and significant impact on quality of life. Traditional antidepressants fall short in terms of efficacy and onset speed, up to 60% of patients. This review delves into the new and emerging pharmacologic treatments for MDD, focusing on their mechanisms of action, clinical effectiveness, and potential to fill the gaps left by conventional therapies. New and emerging treatments in MDD have centered on different neurobiological pathways than the traditional monoaminergic systems. Ketamine and its enantiomer, S-ketamine, have been highlighted for their rapid antidepressant effects, which act through non-competitive N-methyl-d-aspartate (NMDA) receptor antagonism and other pathways involving synaptic plasticity. Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration. Furthermore, the combination of dextromethorphan and bupropion has shown promise. This formulation leverages the NMDA receptor antagonism and sigma-1 receptor agonism of dextromethorphan, complemented by the inhibition of monoamine uptake and metabolism by bupropion, resulting in quicker and more durable antidepressant effects compared with monotherapy. Neurosteroids such as brexanolone and zuranolone, which target γ-aminobutyric acid (GABA)-A receptors, have emerged as effective treatments for postpartum depression. Brexanolone, administered via infusion, and zuranolone, available as an oral formulation, both have demonstrated efficacy in clinical settings. Novel treatments targeting opioid pathways, such as esmethadone, and selective kappa receptor antagonists offer new hope for addressing the symptoms of MDD through mechanisms not traditionally associated with antidepressant action.